An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach-Reference-Cited by-同舟云学术

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

Published:2009-02-15 Issue:4 Volume:115 Page:706-715
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mundle Suneel,Lefebvre Patrick,Vekeman Francis,Duh Mei Scheng,Rastogi Ruchi,Moyo Victor

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey;Steensma;Leukemia Res.,2007

2. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis;Moyo;Ann Hematol.,2008

3. Advances in erythropoietic growth factor therapy for myelodysplastic syndromes;Mundle;Exp Opin Biol Ther.,2006

4. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies;Hellstrom-Lindberg;Br J Haematol.,1995

5. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes;Tehranchi;Med Oncol.,2006

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traitement des syndromes myélodysplasiques de bas risque;Bulletin du Cancer;2023-11

2. Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients;memo - Magazine of European Medical Oncology;2023-08-28

3. Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy;Meditsinskiy sovet = Medical Council;2022-10-06

4. Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2022-03-17

5. Sindromi mielodisplastiche;EMC - AKOS - Trattato di Medicina;2021-06